BR112018076229A2 - formulação tópica e método de tratamento da pele seca pruriginosa causada por ureia de um indivíduo - Google Patents

formulação tópica e método de tratamento da pele seca pruriginosa causada por ureia de um indivíduo

Info

Publication number
BR112018076229A2
BR112018076229A2 BR112018076229-6A BR112018076229A BR112018076229A2 BR 112018076229 A2 BR112018076229 A2 BR 112018076229A2 BR 112018076229 A BR112018076229 A BR 112018076229A BR 112018076229 A2 BR112018076229 A2 BR 112018076229A2
Authority
BR
Brazil
Prior art keywords
histidine
urea
individual
treatment
topical formulation
Prior art date
Application number
BR112018076229-6A
Other languages
English (en)
Inventor
Menne Torkil
Selmer Johan
Lange Jesper
Georgiou Michelle
Wheeler Derek
Evans David
Original Assignee
Drug Delivery Solutions Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drug Delivery Solutions Aps filed Critical Drug Delivery Solutions Aps
Publication of BR112018076229A2 publication Critical patent/BR112018076229A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a uma formulação tópica compreendendo um nucleófilo, como aminoácidos e a maioria dos polipeptídeos e/ou seus derivados, para uso no tratamento ou na prevenção da pele seca, pruriginosa causada por ureia, como no prurido urêmico, de um indivíduo. o aminoácido pode ser histidina e o derivado pode ser um produto de degradação da histidina, um peptídeo contendo histidina, um peptídeo contendo histidina e um ou mais aminoácidos adicionais e um sal farmaceuticamente aceitável de histidina.
BR112018076229-6A 2016-06-17 2017-06-16 formulação tópica e método de tratamento da pele seca pruriginosa causada por ureia de um indivíduo BR112018076229A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201670438 2016-06-17
DKPA201670438 2016-06-17
DKPA201770225 2017-03-28
DKPA201770225 2017-03-28
PCT/DK2017/050201 WO2017215723A1 (en) 2016-06-17 2017-06-16 Formulation for use in the treatment of uremic pruritus

Publications (1)

Publication Number Publication Date
BR112018076229A2 true BR112018076229A2 (pt) 2019-03-26

Family

ID=60663348

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076229-6A BR112018076229A2 (pt) 2016-06-17 2017-06-16 formulação tópica e método de tratamento da pele seca pruriginosa causada por ureia de um indivíduo

Country Status (10)

Country Link
US (2) US10806721B2 (pt)
EP (2) EP3471720A4 (pt)
JP (3) JP7019684B2 (pt)
KR (3) KR20220143149A (pt)
CN (2) CN115671098A (pt)
AU (2) AU2017283511B2 (pt)
BR (1) BR112018076229A2 (pt)
CA (1) CA3026620C (pt)
RU (1) RU2018146294A (pt)
WO (1) WO2017215723A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115671098A (zh) * 2016-06-17 2023-02-03 药物递送解决方案私人有限责任公司 用于治疗尿毒性瘙痒症的制剂
WO2023194400A1 (en) * 2022-04-06 2023-10-12 Mc2 Therapeutics Ltd Topical formulation for use in the treatment or prevention of itchy dry skin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025645A (en) 1976-01-27 1977-05-24 Jelenko Iii Carl Non-steroid topical agent for alleviating inflammation in mammals
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6573302B1 (en) 1999-09-29 2003-06-03 Medical Merchandising, Inc. Cream utilizing capsaicin
US20060211754A1 (en) 2005-03-16 2006-09-21 Yu Ruey J Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof
US20070065396A1 (en) 2005-09-21 2007-03-22 Tracie Martyn International, Llc Topical macqui berry formulation
JP5168996B2 (ja) * 2007-04-13 2013-03-27 味の素株式会社 アミノ酸類高配合防腐水溶液
FR2916351B1 (fr) * 2007-05-22 2012-12-07 Galderma Res & Dev Composition pharmaceutique comprenant au moins deux composes choisis parmi l'acide pyrrolidone-5-carboxylique, la citrulline, l'arginine et l'asparagine et leur utilisation dans le traitement de la dermatite atopique
US20090017129A1 (en) 2007-07-13 2009-01-15 Ma Or Ze Ev Dead Sea minerals enriched anti-inflammatory pharmaceutical composition for treatment of cutaneous dryness, itching, peeling and tightness, especially in hemodialysis patients and preparation and treatment methods thereof
US8337820B2 (en) 2008-02-13 2012-12-25 Bart Nieuwenhuijsen Composition of a water-soluble sunscreen preparation for acne rosacea
GB0803054D0 (en) * 2008-02-20 2008-03-26 Univ Manchester Medicament
CN102171149B (zh) 2008-07-23 2014-07-23 F·恩斯 生产苏打化学品的组合固体废物、二氧化碳生石灰喷射、盐水和反渗透/离子交换法
FR2938193B1 (fr) * 2008-11-07 2011-08-12 Expanscience Lab Medicament ou composition dermatologique comprenant un extrait peptidique d'avocat destine au traitement et a la prevention du prupit
NZ595775A (en) * 2008-12-26 2013-07-26 Glenmark Pharmaceuticals Sa Fused imidazole derivatives as trpv3 antagonist
DE102011110909A1 (de) * 2011-08-18 2013-02-21 Paul Hartmann Ag Zusammensetzungen mit einer die Hautbarriere verbessernden Wirkstoffkombination
US9290489B2 (en) * 2012-07-06 2016-03-22 Duke University Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch
WO2012143576A2 (en) 2012-08-23 2012-10-26 Symrise Ag Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
CN103908467B (zh) * 2013-01-05 2017-02-08 西藏博睿生物科技有限公司 一种药物组合物及制剂
CN115671098A (zh) * 2016-06-17 2023-02-03 药物递送解决方案私人有限责任公司 用于治疗尿毒性瘙痒症的制剂

Also Published As

Publication number Publication date
US20210000796A1 (en) 2021-01-07
JP2019518084A (ja) 2019-06-27
KR20240100484A (ko) 2024-07-01
EP3471720A1 (en) 2019-04-24
KR102454777B1 (ko) 2022-10-14
AU2017283511A1 (en) 2019-01-17
AU2020202785A1 (en) 2020-05-14
JP2022187022A (ja) 2022-12-15
RU2018146294A (ru) 2020-07-17
CN109414430A (zh) 2019-03-01
CN115671098A (zh) 2023-02-03
CA3026620C (en) 2022-09-20
KR20190020022A (ko) 2019-02-27
CA3026620A1 (en) 2017-12-21
JP2022048311A (ja) 2022-03-25
US20190321336A1 (en) 2019-10-24
AU2020202785B2 (en) 2022-02-24
EP4397368A2 (en) 2024-07-10
WO2017215723A1 (en) 2017-12-21
US10806721B2 (en) 2020-10-20
JP7220316B2 (ja) 2023-02-09
EP3471720A4 (en) 2020-02-05
RU2018146294A3 (pt) 2020-09-08
AU2017283511B2 (en) 2020-02-06
CN109414430B (zh) 2022-11-01
JP7019684B2 (ja) 2022-02-15
KR20220143149A (ko) 2022-10-24

Similar Documents

Publication Publication Date Title
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112014012985A2 (pt) métodos de conservação de composições farmacêuticas injetáveis compreendendo uma ciclodextrina e uma droga hidrofóbica
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112017005736A2 (pt) macrociclos peptidomiméticos e formulações dos mesmos
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112018010234A2 (pt) spray formador de película tópica
BR112012025390B8 (pt) Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
EA201892493A1 (ru) Жидкая композиция нейротоксина, стабилизированная триптофаном или тирозином
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
BR112017009798A8 (pt) profármacos de hgh poliméricos
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]